Overview

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Status:
Completed
Trial end date:
2021-05-27
Target enrollment:
Participant gender:
Summary
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin